Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

By João L. Carapinha

December 20, 2024

The Global Fund to Fight AIDS, Tuberculosis and Malaria recently announced a coordinated effort to expand access to lenacapavir, a new HIV pre-exposure prophylaxis (PrEP) medication. This initiative is driven by several major global health organizations working together to ensure that lenacapavir reaches those who need it most.

Partners Involved

– The Global Fund to Fight AIDS, Tuberculosis and Malaria
– The United States President’s Emergency Plan for AIDS Relief (PEPFAR)
– The Children’s Investment Fund Foundation (CIFF)
– The Bill & Melinda Gates Foundation (BMGF)
– Gilead Sciences, the manufacturer of lenacapavir.

Objective

The primary goal is to provide affordable and equitable access to lenacapavir for HIV PrEP, aiming to reach at least 2 million people over three years in countries supported by PEPFAR and the Global Fund. This initiative is part of a broader effort to significantly reduce global HIV infections and align with the 2030 Sustainable Development Goal of ending HIV/AIDS as a public health threat.

Regulatory Approval

The rollout of lenacapavir for PrEP depends heavily on regulatory approval from the U.S. Food and Drug Administration, as well as recommendations from national pharmaceutical regulators and the World Health Organization (WHO).

Licensing and Affordability

Gilead Sciences has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical companies. This will enable low-cost lenacapavir production and supply for HIV prevention in 120 low- and middle-income countries.

Clinical Efficacy

Lenacapavir has shown promising results in clinical trials, reducing HIV infections by 96% compared to background incidence rates. Furthermore, it has demonstrated superiority over once-daily Truvada. These trials, part of Gilead’s PURPOSE program, involved diverse populations, confirming the efficacy and safety profiles of lenacapavir.

Implementation and Support

The Global Fund, PEPFAR, CIFF, and BMGF will collaborate to support countries and communities in implementing national and sub-national HIV long-acting injectable PrEP programs. This effort will also include working with other global health entities, such as WHO, Unitaid, and UNAIDS.

Community Impact

This initiative aims to meet the needs of individuals at high risk of HIV infection by providing a twice-yearly injectable option, which could significantly improve adherence and sustainability of HIV prevention efforts. This is viewed as a potential game-changer in the fight against HIV/AIDS, especially in regions where daily oral medications might not be feasible or preferred.

In summary, this coordinated effort represents a comprehensive approach aimed at leveraging new technologies and partnerships to make lenacapavir widely accessible. It focuses on equity, accessibility, and long-term sustainability in the pursuit of effective HIV prevention and treatment.

Reference url

Recent Posts

Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerative Colitis Treatment

By HEOR Staff Writer

October 9, 2025

The U.S. Food and Drug Administration has granted Simponi pediatric approval for Johnson & Johnson's Simponi (golimumab), which is intended for children with moderately to severely active ulcerative colitis who weigh at least 15 kg. This historic approval is backed by data from the PURSUIT pr...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS
The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...